• Alias: Autologous CART-19 TCR:4-1BB cells
    • Autologous T-lymphocytes transduced with a modified lentiviral vector expressing a CAR consisting of an anti-CD19 scFv and the zeta chain of the TCR/CD3 complex (CD3-zeta), coupled to the signaling domain of 4-1BB (CD137) resulting in immune-modulating effects by inducing a selective toxicity in CD19-expressing tumor cells. After binding to CD19-expressing cells, the CAR transmits a signal to promote T-cell expansion, activation, target cell elimination, and persistence of the tisagenlecleucel cells. Tisagenlecleucel is prepared from the patient’s peripheral blood cells obtained via leukapheresis.
    • FDA approved on August for adults or children with relapsed/refractory acute lymphoblastic leukemia.
    Other topics in Targeted and Immunotherapy Agents